You are here

Optogenetic Multiparametric Assay for HT Cardiotoxicity Testing

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R42HL112521-02
Agency Tracking Number: R42HL112521
Amount: $1,231,507.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA11-097
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
SAN DIEGO, CA 92121-
United States
DUNS: 612181532
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (858) 461-6859
Business Contact
Phone: (858) 461-6859
Research Institution
LA JOLLA, CA 92037-1005
United States

 () -
 Domestic Nonprofit Research Organization

DESCRIPTION (provided by applicant): Monitoring physiology of individual cardiomyocytes in high throughput has not been reported. The inability to perform high throughput physiological measurements limits many basic and applied studies, including the use of stem cell derived cardiomycoytes in cardiotoxicity testing. Current automated cardiotoxicity tests have poor predictive value because they use tumor cell lines engineered with single channels (e.g. hERG), and physiologically relevant tests are reserved for few candidates during the relatively late stages of development. The poor biological relevance of these models contributes to the high failure rate of drug candidates before FDA approval and even after commercialization. We have automated recording frommyocytes for Calcium Transients, but are still limited by use of electrode devices for pacing that prevents miniaturization beyond 96- well format. Furthermore, Action Potential measurement, the most relevant physiological parameter in excitable cells, isstill reserved to low throughput analysis. We propose several conceptual advances to solve these problems by developing a miniaturized, cell-based optogenetic pacing device for high throughput analysis of human Induced Pluripotent Stem Cell (hIPSC)-derived cardiomyocytes in an automated platform for cell-by-cell cytometric analysis of cardiomyocyte physiology. We will also develop automatic segmentation/analysis of Action Potentials (AP) through fluorescent voltage probes and post-recording tracking to identify the same cells after fixation and immunostaining analysis. Calcium Transient (CT) analysis, already developed in a previous SBIR contract, will converge with AP and post-recording tracking to generate single cell multiparametric measurement of all these endpoints conducted in High Throughput. Extensive evaluation will be conducted with drugs that alter AP through different mechanisms to validate the platform. Preliminary data show that stable cell lines expressing the light-triggered protein Channelrhodopsin-2 (ChR2) will electrically couple to cardiomyocytes, allowing optically controlled stimulation of AP without disruption of normal cardiomyocyte physiology. Membrane AP can be recorded in cardiomyocytes through voltage probes and are suitable to image segmentation analysis. Automatic CT measurement and hIPSC-derived cardiomyocytes are an effective model to test cardiotoxic effects of reference drugs. The Aims will advance the use of fluorescent probes to measure action potential, calcium flux and cell characteristics in response to the stimulation. Cardiomyocyte physiology will be quantified by image analysis software that records and analyzes single-cell AP and CT in relation to cardiac subtype or specific protein expression. The software will segment the images into single cell recordings, thus all measurements and data analysis will be on a cell-by- cell basis. The format will be evaluated for 384- and 1536-well to conduct screening on hundreds of cells per individual data point (e.g. compound tested), allowing throughput of tens to hundreds of thousands of datapoints in a single screen by the end of the funding period. Channel openers and blockers will be tested to validate the platform. The platform will find applications in basic and applied research, including regenerative medicine research and drug development/safety testing. PUBLIC HEALTH RELEVANCE Large-scale studies of heart safety early during the drug development process are not currently possible or have low value because physiological testing is too arduous to perform on more than a few cells in a single experiment. Here we propose a conceptual advance of a previous design, where we have automated some of the steps enabling moderate throughput but that still rely on traditional methods to stimulate cardiomyocytes and analyze only one parameter relevant to cardiac physiology. We propose to develop a cell-based miniaturized pacing device that is stimulated by light and then activates the cardiomyocytes. We will also automate the process of Action Potential measurement and will link to Calcium Transient and cardiomyocytes subtypes to generate a comprehensive platform that analyze several aspect of cardiomyocyte physiology. The device will enable many applications, including large physiological screening for new cardioactive drugs and early testing of drug candidates for adverse cardiac toxicity, which is a major reason for drug failure during development, costing 2.5 billion annually.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government